Alzheimers Disease Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Alzheimers Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Early Alzheimers Disease
Annovis Bio Inc.760 enrolled83 locationsNCT06709014
Recruiting
Phase 3

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease
Hoffmann-La Roche800 enrolled135 locationsNCT07170150
Recruiting
Phase 3

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Alzheimers Disease
Hoffmann-La Roche13,000 enrolled207 locationsNCT07177352
Recruiting
Phase 3

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease
Hoffmann-La Roche800 enrolled120 locationsNCT07169578
Recruiting
Not Applicable

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

Mild Cognitive ImpairmentAlzheimers Disease
Emory University10 enrolled1 locationNCT06484244
Recruiting
Phase 2Phase 3

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

DementiaAlzheimers DiseaseAlzheimers Disease, Familial
Washington University School of Medicine280 enrolled35 locationsNCT06647498
Recruiting
Phase 2Phase 3

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

DementiaAlzheimers DiseaseAlzheimers Disease, Familial
Washington University School of Medicine280 enrolled35 locationsNCT05552157
Recruiting
Phase 2

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

DementiaAlzheimers DiseaseMild Cognitive Impairment Due to Alzheimer's Disease
Brigham and Women's Hospital16 enrolled1 locationNCT06489548
Recruiting
Not Applicable

Evaluating the Effectiveness of the Health App Recommendation Tool

Alzheimers Disease Related Dementias
University of Pittsburgh15 enrolled1 locationNCT07216716
Recruiting
Not Applicable

University of Central Florida Music Study

DementiaAlzheimers DiseaseDementia Alzheimer Type
University of Central Florida60 enrolled1 locationNCT07306065